Green versus blue: Randomized controlled trial comparing indocyanine green with methylene blue for sentinel lymph node detection in endometrial cancer

What Was Tested

The paper reports a study of Methylene blue (non-peptide stack partner) in the context of endometriosis, published as a randomized controlled trial.

Who Took Part

By PubMed's age tags, the people studied were adults, middle-aged adults, older adults and people over 80, women only.

For this randomized controlled trial, all patients underwent SLN mapping after injection of blue dye on one side of the cervix and ICG on the other side.

Randomization was for the side (right vs. left) on which ICG was used so that each patient's contralateral hemipelvis (HP) served as a control to her ipsilateral HP.

How the Study Was Run

The researchers set it up as a randomized study.

Random assignment meant chance, not the researchers, decided who got Methylene blue (non-peptide stack partner) and who got the comparison, which limits bias.

The researchers performed a two-tailed, normal-approximate McNemar test for paired-matched data.

The primary endpoint was the difference in SLN detection rate for each HP according to the dye used.

What Was Measured

Topics PubMed links to this paper include Body Mass Index, Carcinoma, Coloring Agents, Endometrial Neoplasms, Indocyanine Green, Laparoscopy and Lymphatic Metastasis.

Author keywords: Blue dye, Endometrial cancer, Methylene blue and Sentinel lymph node.

What This Means in Plain Language

The paper is a randomized study of Methylene blue (non-peptide stack partner) in people with endometriosis.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2019 (Gynecologic oncology), a journal based in United States.

More context: the Methylene blue (non-peptide stack partner) compound page, Endometriosis research.